Northrop Grumman reported better-than-expected second-quarter earnings and raised its full-year financial guidance.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
(Bloomberg) -- The biotechnology sector is stealing the US IPO market thunder from artificial intelligence-related listings, delivering standout returns as bankers line up a steady stream of summer debuts.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Cam
Microsoft has agreed to spend billions of dollars on Mistral's computing infrastructure in Europe under a deal that will also expand distribution of the French AI startup's technology through the U.S. cloud and software giant, the companies said on Tuesday. As part of the agreement, Microsoft Azure customers will be able to develop software using Mistral's data centers in France, giving Microsoft more capacity in Europe and regulated industries an alternative to U.S.-controlled infrastructure. Mistral, meanwhile, has added its AI models called Medium 3.5 and OCR 4 to Microsoft's app builder known as Foundry.
The deal, structured as an all-stock transaction, gives Tempus control of Personalis' NeXT Personal cancer detection test
Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom. Novo Nordisk Inc. filed a lawsuit in the U.S. District Court for the District of New Jersey against Eli Lilly and Company and Lilly USA, LLC, alleging multiple violations of federal and state false advertising and unfair competition laws under the Lanham Act. The lawsuit takes aim at Lilly’s aggressive direct-to-consumer (DTC) advertising campaigns for its blockb
Microchip Technology is scheduled to post its first-quarter results soon, and analysts predict a triple-digit surge in the company’s bottom-line figure.
Two industrial giants report Q2 results on the same day, and analysts are anything but neutral between them. Before you decide which earnings announcement to watch on July 22, you need to see how these two stack up across every dimension Wall Street actually measures.
Vicor (VICR) delivered earnings and revenue surprises of +67.74% and +3.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Ozempic maker Novo Nordisk has filed a lawsuit against Eli Lilly, arguing it uses deceptive advertising to mislead consumers. The complaint accuses Eli Lilly of using outdated studies to promote its branded GLP-1 drugs, Mounjaro and Zepbound, as helping consumers lose significantly more weight on average than Novo Nordisk’s Ozempic and Wegovy.
Memory chip shortages continue to be a problem for most companies.
The first components of an ASML next-generation chipmaking tool arrived at New York state's Albany NanoTech Complex on Tuesday, the governor's office said. The NanoTech complex will use the tool to conduct research and development on future forms of chip design and manufacturing. The NanoTech facility is the only one of its kind in North America, according to NY Creates Director Dave Anderson, and is similar in scope and focus to Europe's Imec, which operates in Belgium.
SpaceX’s IPO was the biggest in history, raising $75 billion at $135 a share.1 The offering sparked much excitement, with retail investors keen on buying into one of the world’s most closely watched companies. If you had invested $2,000 at the $135 IPO price, here’s how much your investment would be worth today, and why […] The post If You Invested $2K in the SpaceX IPO, How Much Do You Have Now? appeared first on SmartReads by SmartAsset.
The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.
The maker of Ozempic and Wegovy says its competitor is misleading consumers by citing outdated weight-loss data in advertisements.
(Bloomberg) -- Strong economic momentum is a double-edged sword for US equity traders. Solid growth is an earnings tailwind. But let it run too hot, and it turns from blessing to curse.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memory Than ComputeUS Strikes Iran in Escalating Campaign After Troops K
📣 “When I look at AI itself, the amount of money being spent is huge. Will it in total pay off? Probably, just like the internet did. Will it pay off the way you expect on the timetable you expect? Definitely not.
By Maggie Fick LONDON, July 21 (Reuters) - Novo Nordisk said on Tuesday it was suing rival Eli Lilly in U.S. federal court, accusing the U.S. drugmaker of false advertising in claiming its weight-loss
A trading boom that carried most of Wall Street to record results this spring also lifted Charles Schwab’s quarterly profits by 32%. The brokerage reported second-quarter net income of $2.8 billion on Tuesday.
(Bloomberg) -- Novo Nordisk A/S is suing Eli Lilly & Co. in US federal court, claiming that Lilly’s advertising for its blockbuster obesity shot Zepbound and diabetes injection Mounjaro is misleading as competition between the two drugmakers escalates.Most Read from BloombergYemen’s Houthis to Impose Maritime Blockade on Saudi ArabiaChina AI Sensation Moonshot’s Gamble on Big Models Pays OffTrump Vows 50% Tariff on Canadian Goods Using Depression-Era LawMoonshot’s Kimi K3 May Be More About Memor
General Motors posted second-quarter net income of $1.31 billion, or $1.41 a share, with revenue rising to $48.03 billion.
Under the deal, Personalis’ minimal residual disease (MRD) test will be integrated into Tempus’ broader oncology portfolio.
The aerospace and defense company posted a profit of $1.09 billion, or $7.68 a share in the second quarter, with sales up 5% at $10.88 billion.
Novo Nordisk has accused arch-rival Eli Lilly of peddling false claims about its weight-loss products in advertising campaigns, marking the latest...
Halliburton stock declines after the oilfield services company posts slightly better-than-expected earnings but sees the war in the Middle East take its toll on business.
Automaker beats forecasts but shares move lowerGeneral Motors Co. (NYSE:GM) reported stronger-than-expected second-quarter results on Tuesday, surpassing Wall Street forecasts for both earnings and revenue while increasing its financial guidance for the second time this year.
The company recently announced some weaker-than-expected earnings and hinted at more potential trouble ahead.
Block is set to report Q2 earnings next month, and analysts expect its EPS to dip by double digits.

<body><p>STORY: From Anthropic's class action settlement to the world AI conference in Shanghai... This is Tech Weekly.</p><p>:: Tech Weekly</p><p>A federal judge has approved Anthropic's $1.5 billion class action settlement...</p><p>the largest known in a U.S. copyright case.</p><p>A group of writers sued Anthropic in 2024, arguing that the company used pirated versions of their books without permission to train its Claude AI model.</p><p>The lawsuit is one of dozens brought by copyright owners against tech companies over the training of large language models.</p><p>Tennessee state has claimed Instagram's design is to blame for a youth mental-health crisis.</p><p>Meta Platforms went to court on Monday – one of several trials in the coming weeks...</p><p>on allegations that the company's social media platforms were intentionally built to be addictive.</p><p>The lawsuit claims Meta failed to disclose extensive internal research..</p><p>showing Instagram could harm teens.</p><p>A Meta spokesperson previously said in a statement that the company already has built-in controls to protect teens.</p><p>Ongoing conflicts shaped discussions at the Farnborough Airshow, one of the world's largest aerospace and defense gatherings.</p><p>The show brings together hundreds of companies across commercial aviation, propulsion and military technology...</p><p>from unmanned fighter jets and hypersonic missiles to spy satellites and AI-enabled weapons systems.</p><p>Defense companies made up half of a record 1,600 exhibitors at this year's show.</p><p>Apple overtook Nvidia to become the world's most valuable company...</p><p>reshuffling the top ranks of tech giants as investors reassess the outlook for AI.</p><p>The shift in the pecking order illustrates how investors are looking beyond the most obvious beneficiaries of the AI boom, such as Nvidia.</p><p>The 2026 World Artificial Intelligence Conference kicked off in Shanghai...</p><p>showcasing the shifting AI landscape with Chinese open-weight AI models making rapid gains against systems from U.S. companies such as OpenAI and Anthropic.</p><p>Huawei's Atlas 950 SuperPoD large-scale AI computing system made its public debut...</p><p>demonstrating China's efforts to produce tech without U.S. giant Nvidia's most advanced chips. </p><p>Li Tianyi was an exhibitor at the show.</p><p>"We work in AI applications, which are more on the software side. As far as foundation models are concerned, I think we're still slightly behind. But it's not a gap that can't be closed. At least after visiting the exhibition today, I feel confident that we can catch up with the U.S. in terms of foundation model capabilities within a relatively short period. Perhaps three to five years."</p><p>An entire hall of humanoid companies also showcased robots dancing, weight lifting and looking eerily human like. </p></body>
Find insight on Novartis, ResMed and more in the latest Market Talks covering the health care sector.